Larimar Therapeutics price target lowered to $15 from $17 at Wedbush

Wedbush lowered the firm’s price target on Larimar Therapeutics (LRMR) to $15 from $17 and keeps an Outperform rating on the shares. Larimar management received additional FDA feedback on its nomlabofusp regulatory filing requirements which includes specificity on the size of the required safety database, and while the clarity is positive, this will extend the filing timeline to 2Q26 from year-end 2025, the analyst tells investors in a research note. The firm is moving out its launch timing for nomlabofusp in the U.S. by about one quarter as the prior estimates assumed initial launch in 1Q27, and says that while the delay is “disappointing,” this is offset by clarity on the regulatory package.